BNTX250117C47500
- 0.00
- 0.000.00%
BioNTech Newsroom
BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst
Truist Financial Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $172
This week's U.S. stock market winners | The technology event CES ignited stock prices! Micron Technology rose over 10% during the week; is the pullback a buying opportunity? The second-hand car platform Carvana saw a rebound this week.
This week, the Dow Jones Industrial Average decreased by 0.23%, closing at 42,635.2 points; during the same period, the S&P 500 Index fell by 0.41%, closing at 5,918.25 points; the Nasdaq fell by 0.73%, closing at 19,478.88 points.
BioNTech Analyst Ratings
Truist Financial Initiates BioNTech(BNTX.US) With Buy Rating, Announces Target Price $172
U.S. Stock Market Gold Rush | Riding the NVIDIA Wave! Autonomous driving company AUR's stock price surged nearly 30% overnight; concerns over gas shortages arise again in Europe, with several Oil & Gas stocks reaching new highs for the year.
The Bird Flu virus is rampant, and the USA reports the first death case! Vaccine manufacturer Moderna surged by 11% upon hearing the news; bullish factors are stacking up! Xiaopeng Autos rose over 9% overnight, and the stock price has increased for three consecutive days.
Arbutus Could Benefit From Big Pharma Bird Flu Vaccines: Jefferies
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside
Moderna, Novavax and Other Vaccine Names Extend Gains Amid COVID/flu Concerns
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
Moderna Stock Jumps Amid Bird Flu Vaccine Hope After First U.S. Death -- Barrons.com
Shares of Vaccine Makers Are Trading Higher After the First Bird Flu Death Was Reporting in the US. Additionally, a Recent DCD Report Noted an Increase in Acute Respiratory Illness Activity.
Private Equity Firms Who Hold 43% of BioNTech SE (NASDAQ:BNTX) Gained 6.8%, Institutions Profited as Well
Vaccine Stocks Gain Amid Uptick in Flu, COVID-19, RSV
BioNTech SE's (NASDAQ:BNTX) Shareholders Might Be Looking For Exit
Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Ascendis Pharma (ASND) and BioNTech SE (BNTX)
NIH Settlement 'Manageable Headwind' for BioNTech, Pfizer, Says Morgan Stanley
Here Are Morgan Stanley's Key Oncology Catalysts for 2025
Sector Update: Health Care Stocks Lower in Afternoon Trading
BioNTech reached a settlement payment of up to 1.26 billion dollars regarding the COVID-19 vaccine.
The German pharmaceutical company BioNTech (BNTX.US) announced that it has reached two separate settlement agreements regarding royalty payments related to its COVID-19 vaccine with the USA National Institutes of Health and the University of Pennsylvania, totaling $1.26 billion. In collaboration with the USA pharmaceutical company Pfizer (PFE.US) to develop the COVID-19 vaccine, BioNTech stated that it will pay the USA Institutions $0.79 billion to address a notice of default. The Institutions previously indicated that BioNTech had failed to pay the royalties owed for the licensing of its vaccine development patents. In addition, the company will pay approximately $0.47 billion to the University of Pennsylvania.